Oral Semaglutide and Cardiovascular Outcomes in High-Risk ...
2025年3月29日 · The Semaglutide Cardiovascular Outcomes Trial (SOUL) was designed to assess the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and …
Semaglutide and Cardiovascular Outcomes in Patients with …
2016年11月10日 · The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-life of approximately 1 week, in type 2 diabetes are unknown.
High-Dose Semaglutide (Up to 16 mg) in People With Type 2 ...
2025年4月25日 · Studies have demonstrated dose-dependent efficacy of glucagon-like peptide 1 receptor agonists for glycemic control and body weight. The aim of this trial was to …
Semaglutide and Walking Capacity in People With Symptomatic ...
2025年3月29日 · Description: The goal of the phase 3b trial was to evaluate the safety of once-weekly injections of the GLP-1 receptor agonist semaglutide and to determine whether it …
Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus
3 天之前 · This real-world, comparative cohort study aims to evaluate the 12-month effectiveness of oral versus subcutaneous semaglutide in patients with type 2 diabetes mellitus (T2D), with a …